The ErbB signaling network: receptor heterodimerization in development and cancer
By Monilola A. Olayioye, Richard M. Neve, H. Lane, Nancy Hynes. EMBO Journal, 2000
1,641 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/a85fab6a6240844a76a5e45e3b02ed123b1c3514
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, positive): “EGFR belongs to the ErbB family of receptors, which includes ErbB1/ EGFR/HER1, ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/HER4.”
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (2004, neutral): “Data collection and refinement statistics ing (Olayioye et al., 2000).”
- Molecular cues to implantation. (2004, neutral): “their ligand specificity and kinase activity (215).”
- Targeting the EGFR signaling pathway in cancer therapy (2012, neutral): “They are transmembrane glycoproteins with molecular weights ranging from 170 to 185 KDa [3].”
- A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008, positive): “In normal tissue, HER2/ErbB2 is known to function as a common coreceptor for the other HER/ErbB receptors (5).”
- Androgen receptor in prostate cancer. (2004, neutral): “Although Her2 apparently enhances AR activity through PI3K and Akt (231), the direct binding of PI3K to Her2 has not been reported (241).”
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (2005, neutral): “Stimulation of the receptor with EGF or other cognate ligands induces receptor dimerization and autophosphorylation, providing docking sites for SH2containing adaptor proteins that mediate the activation of intracellular signaling pathways [1–3].”
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer (2003, neutral): “To date, ten genes have been identified that encode HER ligands [18,19].”
- Phosphotyrosine interactome of the ErbB-receptor kinase family (2005, neutral): “The three other members of the ErbB family are less well studied (Olayioye et al, 2000), although interaction partners have also been identified for a number of phosphotyrosine residues in ErbB2, ErbB3 and ErbB4.”